GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (NAS:ADAG) » Definitions » Short Interest

ADAG (Adagene) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is Adagene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Adagene's Short Interest

For the Biotechnology subindustry, Adagene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adagene's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's Short Interest distribution charts can be found below:

* The bar in red indicates where Adagene's Short Interest falls into.


;
;

Adagene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (NAS:ADAG) » Definitions » Short Interest
Comparable Companies
AVTE IGMS VERU CLSD IVVD VTGN ABOS MNOV CABA TCRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
978:Germany
Address
Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Website
https://www.adagene.com
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.